Candel Therapeutics Inc CADL
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-07-27 |
| Shares Out. | 73,270,000 |
| Website | candeltx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 55 |
| Net Income | -$8.9M |
| Free Cash Flow | -$49.0M |
| Total Assets | $201.9M |
| Total Liabilities | $63.9M |
| Equity | $138.0M |
About Candel Therapeutics Inc
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Candel Therapeutics Inc is a publicly traded company under the ticker symbol CADL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)